Notice: This company has been marked as potentially delisted and may not be actively trading. Cogent Biosciences (UMRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends UMRX vs. AUPH, TVTX, PRAX, HROW, ARVN, ARDX, DAWN, SYRE, CALT, and ANIPShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Aurinia Pharmaceuticals (AUPH), Travere Therapeutics (TVTX), Praxis Precision Medicines (PRAX), Harrow (HROW), Arvinas (ARVN), Ardelyx (ARDX), Day One Biopharmaceuticals (DAWN), Spyre Therapeutics (SYRE), Calliditas Therapeutics AB (publ) (CALT), and ANI Pharmaceuticals (ANIP). These companies are all part of the "medical" sector. Cogent Biosciences vs. Aurinia Pharmaceuticals Travere Therapeutics Praxis Precision Medicines Harrow Arvinas Ardelyx Day One Biopharmaceuticals Spyre Therapeutics Calliditas Therapeutics AB (publ) ANI Pharmaceuticals Aurinia Pharmaceuticals (NASDAQ:AUPH) and Cogent Biosciences (NASDAQ:UMRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, community ranking, analyst recommendations, risk and earnings. Is AUPH or UMRX more profitable? Aurinia Pharmaceuticals has a net margin of -10.23% compared to Cogent Biosciences' net margin of -96.84%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aurinia Pharmaceuticals-10.23% -4.41% -3.07% Cogent Biosciences -96.84%-87.78%-52.14% Does the MarketBeat Community favor AUPH or UMRX? Aurinia Pharmaceuticals received 386 more outperform votes than Cogent Biosciences when rated by MarketBeat users. Likewise, 73.24% of users gave Aurinia Pharmaceuticals an outperform vote while only 68.38% of users gave Cogent Biosciences an outperform vote. CompanyUnderperformOutperformAurinia PharmaceuticalsOutperform Votes57273.24% Underperform Votes20926.76% Cogent BiosciencesOutperform Votes18668.38% Underperform Votes8631.62% Do institutionals & insiders believe in AUPH or UMRX? 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 26.4% of Cogent Biosciences shares are held by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 31.5% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings and valuation, AUPH or UMRX? Cogent Biosciences has lower revenue, but higher earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurinia Pharmaceuticals$220.36M5.87-$78.02M-$0.15-60.20Cogent Biosciences$22.50M14.80-$31.83M-$1.04-7.54 Does the media refer more to AUPH or UMRX? In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 2 mentions for Aurinia Pharmaceuticals and 1 mentions for Cogent Biosciences. Aurinia Pharmaceuticals' average media sentiment score of 0.97 beat Cogent Biosciences' score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate AUPH or UMRX? Aurinia Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 10.74%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aurinia Pharmaceuticals is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurinia Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Cogent Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, AUPH or UMRX? Aurinia Pharmaceuticals has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 3.93, indicating that its stock price is 293% more volatile than the S&P 500. SummaryAurinia Pharmaceuticals beats Cogent Biosciences on 13 of the 18 factors compared between the two stocks. Ad MyBankTrackerYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.View the best savings account rates here Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UMRX vs. The Competition Export to ExcelMetricCogent BiosciencesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$332.96M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-10.3210.5990.1317.19Price / Sales14.80196.061,116.25117.01Price / CashN/A57.1643.1037.85Price / Book7.545.094.784.78Net Income-$31.83M$151.83M$120.31M$225.60M Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UMRXCogent BiosciencesN/A$7.84+0.5%N/A+51.9%$332.96M$22.50M-10.3272News CoverageHigh Trading VolumeAUPHAurinia Pharmaceuticals2.3265 of 5 stars$9.63+2.8%$10.00+3.8%-2.3%$1.38B$220.36M-63.33300TVTXTravere Therapeutics2.5867 of 5 stars$17.50+1.0%$22.62+29.2%+99.1%$1.37B$145.24M-3.81460Positive NewsPRAXPraxis Precision Medicines2.3973 of 5 stars$72.38+3.1%$146.33+102.2%+285.3%$1.35B$2.45M-7.06110High Trading VolumeHROWHarrow2.3758 of 5 stars$36.64+3.2%$63.00+71.9%+221.0%$1.31B$130.19M-37.77182Positive NewsARVNArvinas2.0251 of 5 stars$18.99-2.6%$63.50+234.4%-50.9%$1.30B$78.50M-4.07445ARDXArdelyx3.6947 of 5 stars$5.39+3.3%$10.42+93.3%-23.4%$1.28B$251.85M-17.80267DAWNDay One Biopharmaceuticals1.6159 of 5 stars$12.62-1.0%$35.71+183.0%-10.1%$1.27B$101.95M-12.3860SYRESpyre Therapeutics1.7702 of 5 stars$24.42+1.2%$51.50+110.9%+38.6%$1.26B$890,000.00-3.23100CALTCalliditas Therapeutics AB (publ)0.0667 of 5 stars$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180ANIPANI Pharmaceuticals4.8429 of 5 stars$56.36-0.4%$77.71+37.9%+0.4%$1.19B$555.46M-102.89642Insider TradePositive News Related Companies and Tools Related Companies AUPH Alternatives TVTX Alternatives PRAX Alternatives HROW Alternatives ARVN Alternatives ARDX Alternatives DAWN Alternatives SYRE Alternatives CALT Alternatives ANIP Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UMRX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UMRX Stock Alerts